CLINICAL SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-246475: A SELECTIVE REVERSIBLE P2Y12 RECEPTOR ANTAGONIST.

Juif P. -E.; Boehler M.; Ufer M.; Dingemanse J.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >CLINICAL SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-246475: A SELECTIVE REVERSIBLE P2Y12 RECEPTOR ANTAGONIST.

【24h】

CLINICAL SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-246475: A SELECTIVE REVERSIBLE P2Y12 RECEPTOR ANTAGONIST.

机译：ACT-246475的临床安全，药代动力学和药效学和药效学结果：一种选择性可逆P2Y12受体拮抗剂。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2018年第1期|共1页
作者
Juif P. -E.; Boehler M.; Ufer M.; Dingemanse J.;
展开▼
作者单位

Idorsia Pharmaceut Ltd Allschwil Switzerland;

Idorsia Pharmaceut Ltd Allschwil Switzerland;

Idorsia Pharmaceut Ltd Allschwil Switzerland;

Idorsia Pharmaceut Ltd Allschwil Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. CLINICAL SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-246475: A SELECTIVE REVERSIBLE P2Y12 RECEPTOR ANTAGONIST. [J] . Juif P. -E., Boehler M., Ufer M., Clinical Pharmacology and Therapeutics . 2018,第Suppla1期

机译：ACT-246475的临床安全，药代动力学和药效学和药效学结果：一种选择性可逆P2Y12受体拮抗剂。
2. A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial. [J] . Daniela Baldoni, Shirin Bruderer, Andreas Krause, Clinical drug investigation . 2014,第11期

机译：一项新的可逆且有效的P2Y12受体拮抗剂（ACT-246475）：在首次人体试验中具有耐受性，药代动力学和药效学。
3. PHARMACODYNAMIC EFFECTS OF ORAL REVERSIBLE AND IRREVERSIBLE P2Y12 RECEPTOR ANTAGONISTS ADMINISTERED FOLLOWING SUBCUTANEOUS INJECTION OF SELATOGREL (ACT-246475) [J] . Schilling U., Ufer M., Dingemanse J., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：Selatogrel后施用口服可逆和不可逆P2Y12受体拮抗剂的药效作用（ACT-246475）
4. The Vasodilator-Stimulated Phosphoprotein Assay as a Companion Test to Assess P2Y12 Receptor Activity in Clinical Studies [C] . Lisa K. Jennings, Lisa K Jennings, Jayaprakash Kotha Molecular Medicine TRI-CON. . 2014

机译：血管舒张刺激的磷酸蛋白测定作为评估临床研究中P2Y12受体活性的伴随试验
5. Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor, and Rosuvastatin. [D] . Samineni, Divya. 2011

机译：新型蛋白酶抑制剂Darunavir与瑞舒伐他汀之间药代动力学和药效动力学相互作用的临床前和临床研究。
6. Safety pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594 following inhalation in healthy Japanese volunteers [O] . Susanne Prothon, Ulrika Wählby Hamrén, Ulrika Tehler, 2019

机译：在健康的日本志愿者中吸入后选择性糖皮质激素受体调节剂AZD7594的安全性药代动力学和药效学
7. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin [O] . Steen Husted, Håkan Emanuelsson, Stan Heptinstall, 2006

机译：口腔逆转P2Y12拮抗剂AZD6140与动脉粥样硬化患者的药效学，药代动力学和安全性：与阿司匹林的氯吡格雷的双盲比较

CLINICAL SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-246475: A SELECTIVE REVERSIBLE P2Y12 RECEPTOR ANTAGONIST.

著录项

相似文献

相关主题

期刊订阅